Back to top
more

Gritstone bio (GRTS)

(Delayed Data from NSDQ)

$0.74 USD

0.74
2,410,932

+0.04 (5.70%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $0.74 0.00 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Gritstone bio Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.

Gritstone bio Inc. (GRTS) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Gritstone bio Inc. (GRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine

by Zacks Equity Research

Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 37.74% and -5.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Gritstone bio Inc. (GRTS) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gritstone Oncology, Inc. (GRTS) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 121.74% and 1223.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 0.00% and 12.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology, Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand

by Zacks Equity Research

Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.

Moving Average Crossover Alert: Gritstone Oncology (GRTS)

by Zacks Equity Research

Gritstone Oncology (GRTS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up

by Zacks Equity Research

Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.

Gritstone Oncology, Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 10.39% and -59.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Gritstone Oncology, Inc. (GRTS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gritstone Oncology (GRTS): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Gritstone Oncology Inc (GRTS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology, Inc. (GRTS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Gritstone Oncology, Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.